4.8 Article

Postherpetic Neuralgia

Journal

NEW ENGLAND JOURNAL OF MEDICINE
Volume 371, Issue 16, Pages 1526-1533

Publisher

MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMcp1403062

Keywords

-

Funding

  1. Sanofi Pasteur Merck
  2. GlaxoSmith-Kline
  3. Merck Frosst Canada
  4. Merck
  5. Pfizer
  6. Astellas Pharma through the EuroPain Private-Public Partnership under the European Union Innovative Medicines Initiative Joint Undertaking
  7. Pfizer through the London Pain Consortium
  8. Spinifex Pharmaceuticals
  9. Medivir
  10. Astellas Pharma
  11. Relmada Therapeutics
  12. Asahi Kasei
  13. Nektar Therapeutics through Imperial College Consultants

Ask authors/readers for more resources

A 73-year-old woman presents with persistent pain and itching in the right T10 dermatome from just above the thoracolumbar junction to the umbilicus since a documented episode of herpes zoster in the same region 1 year earlier. She describes a severe, continuous burning pain, unpredictable paroxysms of lancinating pain lasting a few seconds, and intense hypersensitivity to light tactile stimulation, such as clothing brushing against the skin. On physical examination, there are signs of cutaneous scarring throughout the right T10 dermatome, with areas of excoriation caused by scratching. She has patchy loss of tactile perception in this distribution as well as areas of pain provoked by a light brush. Acetaminophen did not help her pain. How would you manage this patient's condition?

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available